
Toward a society where patients have early access to the medicines they need and can choose the treatment that is right for them
Fujitsu Limited signed a strategic partnership agreement with Paradigm Health, Inc. (Paradigm), Fujitsu's Healthy Living Platform, a platform for utilizing medical data, and Fujitsu Kozuchi, an AI service, will facilitate the collection and processing of medical data held by medical institutions, thereby increasing the efficiency of clinical trial planning operations and shortening the time required for clinical trials.
In addition, as a new offering of Healthy Living, Patient-centric Clinical Trials, Fujitsu's LLM-based automated clinical trial document creation service will be available from August 26, 2024.
In the future, Fujitsu will expand the scope of its support not only to clinical trial planning but also to the subsequent execution phase, thereby resolving issues related to the entire clinical trial process. In this way, Fujitsu aims to achieve sales of 20 billion yen in the clinical trial area in fiscal 2030 and contribute to the realization of a society in which patients can obtain necessary drugs at an early stage and can choose the treatment that is right for them.
background
In Japan, patients for clinical trials are dispersed among multiple hospitals, which requires a large amount of time and money to collect the cases needed for clinical trial planning. Combined with measures to suppress drug prices, Japan is increasingly being excluded from regions targeted by global clinical trials designed to develop new drugs on a global scale.
As a result, as of March 2023, there are 143 drugs (Note 2) that are in practical use overseas but unapproved in Japan, and the problem of drug loss, where drugs approved overseas cannot be administered in Japan, is becoming more serious.
Outline of Initiatives
1. accelerate digitalization of clinical trials through partnership with Paradigm
Fujitsu has partnered with Paradigm, a U.S. company that provides one-stop support for pharmaceutical companies and medical institutions in the process of clinical trials from planning to execution, to create a new clinical trial environment that utilizes medical data, which has been difficult to achieve in the past. The partnership will combine Paradigm's clinical trial platform, which boasts an overwhelming number of global clinical trials with Fujitsu's business support know-how, services and cutting-edge technology in the healthcare and life sciences fields in Japan.
Specifically, medical data, genomes, and other clinical data collected from medical institutions through Fujitsu's Healthy Living Platform, a medical data utilization platform, are processed into a format compliant with various regulations using the LLM of Fujitsu Kozuchi, an AI service, and provided to Paradigm Paradigm will also provide the data to Fujitsu Kozuchi's LLM, an AI service. Paradigm analyzes this data on its clinical trial platform and provides pharmaceutical companies with insights necessary for planning and conducting clinical trials. This enables pharmaceutical companies to significantly improve the efficiency of their clinical trial design work.
Medical institutions can also get early information on which trials their patients can participate in on Paradigm's clinical trial platform, making it easier to encourage patients to participate in clinical trials at the right time.
The two companies will deploy these solutions starting in September 2024, beginning with provision to core clinical research hospitals.

2. offer "Patient-centric Clinical Trials," a new offering that improves operational efficiency through clinical trial-specific LLMs.
Hundreds of clinical trial-related documents that pharmaceutical companies need to create for new drug development are still manually created and managed. Fujitsu's clinical trial-specific LLM enables the automated creation of these vast amounts of documents in a regulatory-compliant manner.
Based on Fujitsu's strong track record in the clinical trial field and deep understanding of regulations, existing documents from pharmaceutical companies are automatically converted into a regulatory-compliant data structure. Furthermore, Fujitsu's clinical trial-specific LLM, which enables advanced tasks such as information retrieval, summarization, regulatory-compliant notation, and translation, which were previously performed by skilled professionals, automatically generates clinical trial-related documents from the converted data.
As a result of a demonstration test of this offering with a pharmaceutical company, 80% of each document could be created automatically by LLM. According to Fujitsu's estimate, the time required for document creation is expected to be reduced to 50%. Through this offering, Fujitsu will contribute to improving efficiency and shortening the time required for clinical trial planning at pharmaceutical companies.
About the future
Fujitsu will accelerate the digitalization of the clinical trial environment in Japan by providing comprehensive support for the entire process, including not only clinical trial planning work but also the execution phase of clinical trials, through further alliances with partners and the expansion of offerings. Through these efforts, Fujitsu aims to create the conditions for a large number of global clinical trials to be conducted in Japan and to eliminate drug loss.
Fujitsu will continue to promote its "Healthy Living" initiative, which seeks to improve people's wellbeing, and through the creation of new value by utilizing medical data, contribute to the realization of a society in which each individual can choose his or her own way of life.
Comments from Kent Thoelke, CEO, Paradigm Health, Inc.
Paradigm is very pleased to be working with Fujitsu to maximize its contribution to the efficiency of clinical trial operations in Japan. This partnership will modernize the clinical trial environment and help increase opportunities for patients in Japan to participate in clinical trials. By leveraging Fujitsu's industry-leading clinical trial platform and Fujitsu's broad range of healthcare solutions, we will increase the number of clinical trial options available to patients, reduce the time and cost of drug development, and eliminate drug loss in Japan. We are confident that this will enable Japan to become an integral part of the global clinical trial and drug development ecosystem, while ensuring that Japanese patients have equitable access to the best treatment options.
Trademarks.
Product names and other proper nouns mentioned herein are trademarks or registered trademarks of their respective companies.
[Annotation.
Note 1
Paradigm Health, Inc:
Headquarters: 175 S. 3rd Street, Suite 1000, Columbus, Ohio 43215, United States of America, CEO Kent Thoelke
Note 2
As of March 2023, there are 143 drugs that are in practical use overseas but not yet approved in Japan.
(Source: Ministry of Health, Labour and Welfare website) https://www.mhlw.go.jp/content/11121000/001206963.pdf
Related Link
Healthy Living's introduction page (Japanese only)https://activate.fujitsu/ja/uvance/healthy-living)
Patient-centric Clinical Trials introduction page (https://www.fujitsu.com/jp/solutions/uom/healthy-living/patient-centric-clinical-trials/)
[Press conference materials
August 26, 2024
Fujitsu Limitedhttps://pr.fujitsu.com/jp/news/2024/08/26b.pdf)
Fujitsu's Contribution to the SDGs

The Sustainable Development Goals (SDGs), adopted by the United Nations in 2015, are common goals that the entire world must achieve by 2030. Fujitsu's Purpose (raison d'être), "to make the world more sustainable by bringing trust to society through innovation," is a commitment to contribute to the SDGs.

Fujitsu Limited|Corporate Profile
| name of company | Fujitsu Limited |
| Establishment | Jun. 1935 |
| Location | 4-1-1 Kamikotanaka, Nakahara-ku, Kawasaki-shi, Kanagawa |
| representative | Takahito Tokita |
| uniform resouce locator | https://global.fujitsu/ja-jp |









